Skip to main
IMUX
IMUX logo

Immunic Inc (IMUX) Stock Forecast & Price Target

Immunic Inc (IMUX) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 54%
Buy 38%
Hold 8%
Sell 0%
Strong Sell 0%

Bulls say

Immunic Inc's positive outlook is bolstered by encouraging Phase 1b data demonstrating a dose-dependent increase in GLP-1 levels, which may correlate to potential therapeutic benefits in patients and could facilitate future strategic partnerships for IMU-856. Furthermore, preclinical studies indicate promising outcomes for vidofludimus calcium (IMU-838) regarding its neuroprotective properties and efficacy in reducing body weight gain, suggesting a multifaceted approach to treating multiple sclerosis. With the upcoming top-line data from the CALLIPER trial in April 2025 and continued positive results from the Phase 3 ENSURE program, Immunic is well-positioned to advance its pipeline of innovative immunology therapies.

Bears say

Immunic Inc faces significant risks that contribute to a negative outlook on its stock, including the potential failure of its developmental candidates to achieve projected peak commercial revenues due to factors such as market size, penetration rates, and pricing challenges. Additionally, the company's ability to secure necessary capital resources for ongoing operations is uncertain, which may hinder its growth and development efforts. Furthermore, there are ongoing concerns regarding the progress of program development and commercialization, which could further impact financial sustainability.

Immunic Inc (IMUX) has been analyzed by 13 analysts, with a consensus rating of Buy. 54% of analysts recommend a Strong Buy, 38% recommend Buy, 8% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Immunic Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Immunic Inc (IMUX) Forecast

Analysts have given Immunic Inc (IMUX) a Buy based on their latest research and market trends.

According to 13 analysts, Immunic Inc (IMUX) has a Buy consensus rating as of Aug 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $20.54, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $20.54, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Immunic Inc (IMUX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.